Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorIRCCS San Raffaele

About this trial

The purpose of the study is to evaluate the ability of placental angiogenesis markers to predict the risk of PE in pregnancy in women with primary APS.

To construct reference intervals of placental angiogenesis markers specific to women affected by primary APS in pregnancy by measuring the levels of sFlt-1and PlGF in serum maternal serum and their sFlt-1/PlGF ratio during the trimesters of gestation (I TM, II TM and III TM).

For this aim the study will involve recruiting two groups of subjects, one will be cases and one will be controls.

Eligibility criteria

Qualifiers

Group 1

Pregnant patients between the ages of 18 and 45 years.

Diagnosis of primary APS, according to international classification criteria.

Group 2

Disqualifiers

Group 1

PMA pregnancies.

Known chronic pathology in gestational period such as chronic essential hypertension, neurological pathology

Previous thrombotic event

Trial design

Treatments tested in this trial

  • Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)
  • Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators